No Data
Carna Biosciences: Confirmatory letter.
Carna Biosciences: Interim report - 22nd term (January 1, 2024 - December 31, 2024)
Honda's operating profit in Q1 increased by 22.9%, reaching 484.7 billion yen.
Honda (7267) announced its first quarter results for the fiscal year ending in March 2025, with sales revenue of 5 trillion 404.858 billion yen, a year-on-year increase of 16.9%, and operating profit of 484.705 billion yen, a year-on-year increase of 22.9%. This exceeded the consensus (around 473 billion yen). The global number of passenger carried increased mainly in India and Brazil in the motorcycle business. The strong sales of hybrid models also continued in the four-wheel business. [Positive evaluation] 5858 STG, 79.
Carna Biosciences: Financial results presentation materials for the second quarter of the December 2024 period.
Carna Biosciences: 2nd quarter (interim period) financial statements as of December 2024 (Japanese standard) (consolidated)
Daiwa House, Mazda, NTT, Softbank Group (7th)
※The above calendar is tentative and subject to change due to company circumstances. --------------------------------------- August 7th (Wednesday) <1451> KHC <1719> Ando Hazama <1720> Tokyu Construction <1726> BRHD <1762> Takamatsu G <1833> Okumura Group <1835> Tokei Kogyo <1890> Toyo Construction <189
No Data
